INTRODUCTION Clinical outcomes of human severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) infection range from silent infection to lethal coronavirus …

INTRODUCTION Interindividual clinical variability is vast in humans infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from silent infection to …

Recessive or dominant inborn errors of type I interferon (IFN) immunity can underlie critical
COVID-19 pneumonia in unvaccinated adults. The risk of COVID-19 pneumonia in …

Recessive or dominant inborn errors of type I interferon (IFN) immunity can underlie critical
COVID-19 pneumonia in unvaccinated adults. The risk of COVID-19 pneumonia in …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak quickly
developed into a pandemic in March 2020. To date, no vaccines or antiviral medications are …

A recent work published in Science by Paul Bastard et al. 1 reported that neutralizing auto-
antibodies (auto-Abs) against type I interferons (IFNs) were distinctly found in patients with …

Since 2003, rare inborn errors of human type I IFN immunity have been discovered, each
underlying a few severe viral illnesses. Autoantibodies neutralizing type I IFNs due to rare …

Inborn and acquired deficits of type I interferon (IFN) immunity predispose to life-threatening
COVID-19 pneumonia. We longitudinally profiled the B cell response to mRNA vaccination …

SARS-CoV-2 infection is benign in most individuals but, in around 10% of cases, it triggers
hypoxaemic COVID-19 pneumonia, which leads to critical illness in around 3% of cases …

Recently, a paper published in Science by Hadjadj et al. reported that type I interferon (IFN)
deficiency, could be a hallmark of severe coronavirus disease 2019 (COVID-19) caused by …